September 3, 2024
Unveiling the Future of Biotech: Top 11 Startups to Watch in 2024
Biotech startups, Top biotech companies, Biotechnology industry, Emerging biotech trends, Biotech innovation, Biotech awards
George Medicines Unveils Promising Low-Dose Triple Combination Pill for Hypertension Management
Hypertension, Triple Combination Pill, Low-Dose, Blood Pressure Control, GMRx2, George Medicines
Sanofi’s Tolebrutinib Shows Mixed Results in Phase 3 MS Trials, Plans for FDA Filing Remain
Tolebrutinib, Sanofi, Multiple Sclerosis, Phase 3 Trials, FDA Filing
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
Women Breaking Barriers in Drug Development: Celebrating Leadership and Innovation
Women in drug development, gender equity, STEM, pharmaceutical industry, leadership, innovation
Arrowhead Pharmaceuticals Highlights Key Pancreatitis Data from Phase 3 Lipid Disease Study to Distinguish Itself from Ionis
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Plozasiran, Olezarsen, Severe Hypertriglyceridemia (SHTG), Familial Chylomicronemia Syndrome (FCS), Acute Pancreatitis, RNAi Therapy, Triglyceride Reduction
Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials
Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials
Bayer’s Asundexian Fails to Prevent Strokes, Jeopardizing $5.5 Billion Blockbuster Hopes
Bayer, asundexian, stroke prevention, atrial fibrillation, Factor XI inhibitors, clinical trials
Vutrisiran Shows Promising Results in Phase 3 Study for ATTR-CM Treatment
Vutrisiran, ATTR-CM, Phase 3 Study, Alnylam Pharmaceuticals, HELIOS-B